MSM / Methylsulfonylmethane for Allergic Rhinitis

Verdict: Weak evidence; MSM is not proven for hay fever

MSM (methylsulfonylmethane) is not proven to relieve allergic rhinitis. The only human data come from two small, low-quality trials, so any benefit remains unconfirmed and MSM should not replace established hay-fever treatments.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

This claim earns a Weak (Tier C) grade because the entire human evidence base is just two small, methodologically weak trials. Barrager 2002 (PMID 12006124) was an open-label study of 50 people with no placebo group, so its reported symptom improvements cannot be separated from natural seasonal swings or placebo effect; notably, IgE and histamine did not change, leaving any mechanism unclear. A published commentary (PMID 12165181) further flagged its lack of pollen-count tracking and questionnaire standardization.

The second trial, Hewlings 2018 (PMID 30497995), was double-blind but explicitly exploratory, with only 18 completers. It reported reduced nasal symptom scores and improved nasal airflow at certain doses, but a sample this small is far too underpowered to be conclusive. No placebo-controlled trial of adequate size, and no systematic review or meta-analysis, exists for this question, and no new trials have appeared since.

Regulators and clinicians do not endorse MSM for allergies. The US FDA recognizes MSM only as generally safe for food use, which speaks to safety, not effectiveness. The EU's EFSA rejected MSM-related health claims, and major bodies (NIH/NCCIH, Mayo Clinic, and AAAAI/ACAAI allergy guidelines) do not address or recommend it for allergic rhinitis. Proven options such as intranasal corticosteroids and antihistamines remain the standard of care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.47
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
65%
Broadly consistent
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.47
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (2)L2 · primary research & systematic reviews

A multicentered, open-label trial on the safety and efficacy of methylsulfonylmethane in the treatment of seasonal allergic rh
PMID: 12006124 2002 RCT (open-label) n = 50
Finding: Upper/total respiratory symptoms significantly improved by day 7 (p<0.01 and p<0.005); lower respiratory symptoms improved by week 3 (p<0.001); no significant change in IgE or histamine.
🟠 Limited quality
View on PubMed
Evaluating the Impacts of Methylsulfonylmethane on Allergic Rhinitis After a Standard Allergen Challenge: Randomized Double-Bli
PMID: 30497995 2018 RCT (double-blind) n = 18
Finding: 3g/day MSM significantly decreased all nasal symptoms and increased PNIF (p=0.01); acute 12g dose reduced VAS symptoms by 22.49% (p=0.03); low-dose chronic arm reduced symptoms 53.72% (p=0.001).
🟠 Limited quality Effect size: VAS reduction: 22.49%–53.72% depending on dosing arm
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Supportive
FDA has no questions regarding Bergstrom Nutrition's conclusion that methylsulfonylmethane is generally recognized as safe under the intended conditions of use. source↗
L4b EU EFSA
Against
L4d TW TFDA / 衛福部
Neutral
每日食用限量為六公克,且單一次劑量不得超過二公克。使用甲基硫醯基甲烷作為原料之食品,應標示「避免睡前食用,孕婦及哺乳期婦女使用前應先諮詢醫師」之警語字樣。 source↗
L5e Specialty Society (condition-mapped)
Not addressed
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬2 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-allergic-rhinitis-INT-methylsulfonylmethane-001 繁體中文版 →